6269-25-6

Usage

Uses

Used in Pharmaceutical Research:
2-(Hydroxymethyl)-5-methoxy-4H-pyran-4-one is used as an inhibitor of HIV-1 for the purpose of assessing its potential as a therapeutic agent in the treatment of HIV/AIDS. Its ability to inhibit the virus makes it a valuable candidate for further research and development in the field of antiviral medications.

InChI:InChI=1/C7H8O4/c1-10-7-4-11-5(3-8)2-6(7)9/h2,4,8H,3H2,1H3

Upstream product

• 501-30-4 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one 
• 77-78-1 dimethyl sulfate 
• 40838-34-4 2-chloromethyl-5-methoxy-4H-pyran-4-one 
• 74-83-9 methyl bromide 
• 74-88-4 methyl iodide 
• 186581-53-3 diazomethane 

Downstream Products

• 898838-01-2 5-methoxy-4-(4-methoxybenzyloxy)-2-pyridinecarboxaldehyde 
• 898838-00-1 [5-methoxy-4-(4-methoxybenzyloxy)pyridin-2-yl]methanol 
• 898838-04-5 (3-hydroxy-2-isobutylpyridin-4-yl)(5-methoxy-4-(4-methoxybenzyloxy)pyridin-2-yl)methanone 
• 1026170-93-3 (2-isobutyl-3-methoxymethoxy-pyridin-4-yl)-[5-methoxy-4-(4-methoxy-benzyloxy)-pyridin-2-yl]-methanol 
• 898838-03-4 (2-isobutyl-3-(methoxymethoxy)pyridin-4-yl)(5-methoxy-4-(4-methoxybenzyloxy)pyridin-2-yl)methanone 
• 898838-05-6 2-isobutyl-4-(5-methoxy-4-(4-methoxybenzyloxy)-2-pyridinoyl)pyridin-3-yl trifluoromethanesulfonate 
• 62885-42-1 4-Hydroxy-2-hydroxymethyl-5-methoxypyridin 
• 6266-91-7 5-methoxy-2-methyl-4H-pyran-4-one 
• 1091682-22-2 (1-{(S)-2-[(R)-3-(benzyloxy-formyl-amino)-2-cyclopentylmethyl-propionylamino]-3,3-dimethyl-butyryl}-piperidin-4-yl)-(5-methoxy-4-oxo-4H-pyran-2-ylmethyl)-carbamic acid 2,2,2-trichloro-ethyl ester 
• 1091682-24-4 (R)-3-(benzyloxy-formyl-amino)-2-cyclopentylmethyl-N-((S)-1-{4-[(5-methoxy-4-oxo-4H-pyran-2-ylmethyl)-amino]-piperidine-1-carbonyl}-2,2-dimethyl-propyl)-propionamide 
• 103878-33-7 4-chloro-5-methoxypicolinic acid 
• 857433-67-1 methyl 4-chloro-5-methoxypyridine-2-carboxylate 
• 51727-04-9 4-Hydroxy-5-methoxypyridin-2-carbonsaeure 
• 50700-60-2 3-methoxy-4(1H)-pyridone 

Relevant academic research and scientific papers

NOVEL ISOINDOLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF

Disclosed are a novel isoindoline derivative, a pharmaceutical composition and use thereof. The compound of formula I, or the pharmaceutically acceptable salt, solvate, polymorph, co-crystal, stereoisomer, isotopic compound, metabolite or prodrug thereof disclosed in the invention can regulate the generation and/or activity of PDE4 and/or TNF-α so as to effectively treat cancer and inflammatory diseases.

The issue of misidentification of kojic acid with flufuran in aspergillus flavus

In the course of investigations on the complex phenomenon of bee decline, Aspergillus flavus was isolated from the haemocoel of worker bees. Observations on the metabolomic profile of this strain showed kojic acid to be the dominant product in cultures on Czapek-Dox broth. However, an accurate review of papers documenting secondary metabolite production in A. flavus also showed that an isomer of kojic acid, identified as 5-(hydroxymethyl)-furan-3-carboxylic acid and named flufuran is reported from this species. The spectroscopic data of kojic acid were almost identical to those reported in the literature for flufuran. This motivated a comparative study of commercial kojic acid and 5-(hydroxymethyl)-furan-3-carboxylic acid, highlighting some differences, for example in the 13C-NMR and UV spectra for the two compounds, indicating that misidentification of the kojic acid as 5-(hydroxymethyl)-furan-3-carboxylic acid has occurred in the past.

INHIBITORS OF BRUTON'S TYROSINE KINASE

The present invention relates to a new compound of formula I: or pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein: V1 is C or N, V2 is C(R2) or N, whereby if V1 is C then V2 is N, if V1 is C then V2 is C(R2), or if V1 is N then V2 is C(R2); each n, k is independently 0, 1; each R2, R11 is independently H, D, Hal, CN, NR'R", C(O)NR'R", C1-C6 alkoxy; R3 is H, D, hydroxy, C(O)C1-C6 alkyl, C(O)C2-C6 alkenyl, C(O)C2-C6 alkynyl, C1-C6 alkyl; R4 is H, Hal, CN, CONR'R", hydroxy, C1-C6 alkyl, C1-C6 alkoxy; L is CH2, NH, O or chemical bond; R1 is selected from the group of the fragments, comprising: Fragment 1, Fragment 2, Fragment 3 each A1, A2, A3, A4 is independently CH, N, CHal; each A5, A6, A7, A8, A9 is independently C, CH or N; R5 is H, CN, Hal, CONR'R", C1-C6 alkyl, non-substituted or substituted by one or more halogens; each R' and R" is independently selected from the group, comprising H, C1-C6 alkyl, C1-C6 cycloalkyl, aryl; R6 is selected from the group: [formula II] each R7, R8, R9, R10 is independently vinyl, methylacetylenyl; Hal is CI, Br, I, F, which have properties of inhibitor of Bruton's tyrosine kinase (Btk), to pharmaceutical compositions containing such compounds, and their use as pharmaceuticals for treatment of diseases and disorder.

Anthraquinone acid curved ester compound and its as tyrosinase inhibitors (by machine translation)

The invention of formula (I) of the anthraquinone acid curved ester compound synthesis and of such compounds in the inhibition of tyrosinase in the application. In vitro inhibition of the tyrosinase screening results show that: anthraquinone acid curved ester has a strong inhibiting tyrosinase activity, inhibiting activity superior to that of the kojic acid. The invention relates to a compound of novel structure, simple preparation, pharmaceutical, cosmetics and food preservation field and has a wide application. The anthraquinone acid curved ester compound of the following formula shown in chemical structural formula, wherein R1 For [...] acyl, R2 Hydrogen, methyl, benzyl. Formula (I). (by machine translation)

Kojic gallate compounds and application thereof as tyrosinase inhibitor

The invention relates to synthesis of kojic gallate compounds in a formula (I) and an application of the compounds in inhibiting tyrosinase. Screening results of in-vitro inhibition of tyrosinase showthat kojic gallate has higher tyrosinase inhibiting activity and is superior to positive control, namely, kojic acid. The compounds have novel structure, are simple to prepare and have broad application prospects in the field of medicines, cosmetics and food preservation. The chemical structural formula of the kojic gallate compounds is shown in the description, wherein R is hydrogen, methyl andbenzyl.

6-MEMBERED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

A compound represented by Formula (I): wherein or the like Y1 is O or the like; Z1 is C(R4) or N; Z2a is C(R5a) or the like; Z3a is C(R6) or the like; R4, R5a and R6 are each independently a hydrogen atom or the like; R1 is substituted or unsubstituted aromatic carbocyclyl or the like; R2a, R2b, R2c and R2d are each independently a hydrogen atom or the like; X is N(R7a) or the like; R7a is a hydrogen atom or the like; R3 is or the like Ring B is a 6-membered aromatic carbocycle or the like; R9a and R10a are each independently halogen or the like; n is an integer from 1 to 5; m is an integer from 0 to 4; and p1 is an integer from 0 to 3, or a pharmaceutically acceptable salt thereof.

Synthetic method for amino-containing hydroxypyridone compound

The invention discloses a synthetic method for an amino-containing 3-hydroxypyridine-4-ketone iron chelating agent as shown in a formula (III) which is described in the specification. The synthetic method comprises the following steps: with methyl-protected azido hydroxypyridone as shown in a formula (I) which is described in the specification as a raw material, allowing the methyl-protected azido-hydroxypyridine to generate reduction and demethylation reactions under the protection of boron tribromide as shown in a formula (II) which is described in the specification, a solvent A and gas B, after completion of the reactions, carrying out quenching with a solvent C, and carrying out post-treatment so as to obtain the amino-containing 3-hydroxypyridine-4-ketone compound as shown in the formula (III). Compared with a conventional method, the synthetic method provided by the invention adopts a boron tribromide reagent with mild reaction conditions, avoids the use of a metal catalyst, andhas simple and convenient operation and high reaction yield.

HETEROARYLBENZIMIDAZOLE COMPOUNDS

The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative and/or inflammatory disorders, as a sole agent or in combination with other active ingredients.

NITROGEN-CONTAINING HETEROCYCLIC COMPOUND

The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as a medicament such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the attached DESCRIPTION.

Systematic comparison of the mono-, dimethyl-and trimethyl 3-hydroxy-4(1H)-pyridones-Attempted optimization of the orally active iron chelator, deferiprone

A range of close analogues of deferiprone have been synthesised. The group includes mono-, di-and trimethyl-3-hydroxy-4(1H)-pyridones. These compounds were found to possess similar pFe3+ values to that of deferiprone, with the exception of the 2.5-dimethylated derivatives. Surprisingly the NHcontaining hydroxy-4(1H)-pyridones were found to be marginally more lipophilic than the corresponding N-Me containing analogues. This same group are also metabolised less efficiently by Phase 1 hydroxylating enzymes than the corresponding N-Me analogues. As result of this study, three compounds have been identified for further investigation centred on neutropenia and agranulocytosis.